The specter of generic challenges has long loomed over copyright’s famous drug, Viagra, raising questions about the future of similar drug stakes. While first periods saw substantial gains, the exclusivity expiration has opened the path for cheaper alternatives, likely diminishing profitability and posing a genuine risk for shareholders looking f